An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G. Wysham, Donald R. Sullivan, Gopal Allada

Research output: Contribution to journalArticle

70 Scopus citations


We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Original languageEnglish (US)
Pages (from-to)1478-1479
Number of pages2
Issue number5
StatePublished - May 2013


ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this